Microbot Medical Inc. (NASDAQ:MBOT) Short Interest Update

Microbot Medical Inc. (NASDAQ:MBOT) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 173,300 shares, an increase of 93.4% from the March 15th total of 89,600 shares. Based on an average daily trading volume, of 100,600 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Microbot Medical

Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its holdings in Microbot Medical by 6,713.4% during the 2nd quarter. Wells Fargo & Company MN now owns 12,741 shares of the biotechnology company’s stock worth $35,000 after buying an additional 12,554 shares in the last quarter. Hilltop Holdings Inc. acquired a new stake in Microbot Medical during the 2nd quarter worth approximately $52,000. Virtu Financial LLC lifted its holdings in Microbot Medical by 75.9% during the 4th quarter. Virtu Financial LLC now owns 42,046 shares of the biotechnology company’s stock worth $69,000 after buying an additional 18,138 shares in the last quarter. Cetera Advisor Networks LLC acquired a new stake in shares of Microbot Medical in the 1st quarter valued at $78,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Microbot Medical by 52.5% in the 1st quarter. Renaissance Technologies LLC now owns 15,695 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 5,400 shares in the last quarter. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Stock Down 2.7 %

Microbot Medical stock opened at $1.08 on Friday. The firm has a market cap of $15.55 million, a PE ratio of -1.00 and a beta of 1.64. Microbot Medical has a 52-week low of $1.00 and a 52-week high of $4.37. The company’s 50 day moving average is $1.23 and its two-hundred day moving average is $1.30.

About Microbot Medical

Microbot Medical Inc operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.